Abstract
Whereas stereochemical purity in drugs has become the standard for small molecules, stereoisomeric mixtures containing as many as a half million components persist in antisense oligonucleotide (ASO) therapeutics because it has been feasible neither to separate the individual stereoisomers, nor to synthesize stereochemically pure ASOs. Here we report the development of a scalable synthetic process that yields therapeutic ASOs having high stereochemical and chemical purity. Using this method, we synthesized rationally designed stereopure components of mipomersen, a drug comprising 524,288 stereoisomers. We demonstrate that phosphorothioate (PS) stereochemistry substantially affects the pharmacologic properties of ASOs. We report that Sp-configured PS linkages are stabilized relative to Rp, providing stereochemical protection from pharmacologic inactivation of the drug. Further, we elucidated a triplet stereochemical code in the stereopure ASOs, 3′-SpSpRp, that promotes target RNA cleavage by RNase H1 in vitro and provides a more durable response in mice than stereorandom ASOs.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Crooke, S.T. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1489, 31–44 (1999).
Deleavey, G.F. & Damha, M.J. Designing chemically modified oligonucleotides for targeted gene silencing. Chem. Biol. 19, 937–954 (2012).
Swayze, E.E. et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687–700 (2007).
Sharma, V.K., Sharma, R.K. & Singh, S.K. Antisense oligonucleotides: modifications and clinical trials. MedChemComm. 5, 1454–1471 (2014).
Eckstein, F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 24, 374–387 (2014).
Crooke, S.T. & Geary, R.S. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br. J. Clin. Pharmacol. 76, 269–276 (2013).
Stec, W.J., Grajkowski, A., Koziolkiewicz, M. & Uznanski, B. Novel route to oligo(deoxyribonucleoside phosphorothioates). Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside phosphorothioates). Nucleic Acids Res. 19, 5883–5888 (1991).
Stec, W.J. et al. Deoxyribonucleoside 3′-O-(2-thio- and 2-oxo-“spiro”-4,4-pentamethylene-1,3,2-oxathiaphospholane)s: monomers for stereocontrolled synthesis of oligo(deoxyribonucleoside phosphorothioate)s and chimeric PS/PO Oligonucleotides. J. Am. Chem. Soc. 120, 7156–7167 (1998).
Iyer, R.P., Yu, D., Ho, N.-H., Tan, W. & Agrawal, S. A novel nucleotide phosphoramidite synthon derived from1R, 2S-ephedrine. Tetrahedron Asymmetry 6, 1051–1054 (1995).
Guo, M., Yu, D., Iyer, R.P. & Agrawal, S. Solid-phase stereoselective synthesis of 2′-O-methyl-oligoribonucleoside phosphorothioates using nucleoside bicyclic oxazaphospholidines. Bioorg. Med. Chem. Lett. 8, 2539–2544 (1998).
Wilk, A., Grajkowski, A., Phillips, L.R. & Beaucage, S.L. Deoxyribonucleoside cyclic N-acylphosphoramidites as a new class of monomers for the stereocontrolled synthesis of oligothymidylyl- and oligodeoxycytidylyl- phosphorothioates. J. Am. Chem. Soc. 122, 2149–2156 (2000).
Oka, N., Yamamoto, M., Sato, T. & Wada, T. Solid-phase synthesis of stereoregular oligodeoxyribonucleoside phosphorothioates using bicyclic oxazaphospholidine derivatives as monomer units. J. Am. Chem. Soc. 130, 16031–16037 (2008).
Nukaga, Y., Yamada, K., Ogata, T., Oka, N. & Wada, T. Stereocontrolled solid-phase synthesis of phosphorothioate oligoribonucleotides using 2′-O-(2-cyanoethoxymethyl)-nucleoside 3′-O-oxazaphospholidine monomers. J. Org. Chem. 77, 7913–7922 (2012).
Oka, N., Kondo, T., Fujiwara, S., Maizuru, Y. & Wada, T. Stereocontrolled synthesis of oligoribonucleoside phosphorothioates by an oxazaphospholidine approach. Org. Lett. 11, 967–970 (2009).
Li, M. et al. Synthesis and cellular activity of stereochemically-pure 2′-O-(2-methoxyethyl)-phosphorothioate oligonucleotides. Chem. Commun. (Camb.) 53, 541–544 (2017).
Iwamoto, N., Oka, N., Sato, T. & Wada, T. Stereocontrolled solid-phase synthesis of oligonucleoside H-phosphonates by an oxazaphospholidine approach. Angew. Chem. Int. Edn Engl. 48, 496–499 (2009).
Brill, W.K.-D. Thioalkylation of nucleoside-H-phosphonates and its application to solid phase synthesis of oligonucleotides. Tetrahedr. Lett. 36, 703–706 (1995).
Nielsen, J. & Caruthers, M.H. Directed Arbuzov-type reactions of 2-cyano-1,1-dimethylethyl deoxynucleoside phosphites. J. Am. Chem. Soc. 110, 6275–6276 (1988).
Nowotny, M. et al. Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol. Cell 28, 264–276 (2007).
Boczkowska, M., Guga, P. & Stec, W.J. Stereodefined phosphorothioate analogues of DNA: relative thermodynamic stability of the model PS-DNA/DNA and PS-DNA/RNA complexes. Biochemistry 41, 12483–12487 (2002).
Oka, N. & Wada, T. Stereocontrolled synthesis of oligonucleotide analogs containing chiral internucleotidic phosphorus atoms. Chem. Soc. Rev. 40, 5829–5843 (2011).
Koziołkiewicz, M. et al. Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: diastereoselectivity of plasma 3′-exonuclease. Antisense Nucleic Acid Drug Dev. 7, 43–48 (1997).
Lima, W.F. et al. Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol. Pharmacol. 71, 83–91 (2007).
Koziolkiewicz, M., Krakowiak, A., Kwinkowski, M., Boczkowska, M. & Stec, W.J. Stereodifferentiation--the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H. Nucleic Acids Res. 23, 5000–5005 (1995).
Yu, D. et al. Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties. Bioorg. Med. Chem. 8, 275–284 (2000).
Watts, J.K. & Corey, D.R. Silencing disease genes in the laboratory and the clinic. J. Pathol. 226, 365–379 (2012).
Linton, M.F. et al. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92, 3029–3037 (1993).
Prakash, T.P. et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42, 8796–8807 (2014).
Reaven, G.M., Mondon, C.E., Chen, Y.D. & Breslow, J.L. Hypertriglyceridemic mice transgenic for the human apolipoprotein C-III gene are neither insulin resistant nor hyperinsulinemic. J. Lipid Res. 35, 820–824 (1994).
Wan, W.B. et al. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. Nucleic Acids Res. 42, 13456–13468 (2014).
Stec, W.J. et al. Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: proof of sequence specificity in cell culture and in vivo rat experiments. Antisense Nucleic Acid Drug Dev. 7, 567–573 (1997).
Krieg, A.M., Guga, P. & Stec, W. P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides 13, 491–499 (2003).
Bumcrot, D., Manoharan, M., Koteliansky, V. & Sah, D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2, 711–719 (2006).
Jahns, H. et al. Stereochemical bias introduced during RNA synthesis modulates the activity of phosphorothioate siRNAs. Nat. Commun. 6, 6317 (2015).
Hammond, S.M. & Wood, M.J. Genetic therapies for RNA mis-splicing diseases. Trends Genet. 27, 196–205 (2011).
Østergaard, M.E. et al. Efficient synthesis and biological evaluation of 5′-GalNAc conjugated antisense oligonucleotides. Bioconjug. Chem. 26, 1451–1455 (2015).
Aaronson, J.G. et al. Rapid HATU-mediated solution phase siRNA conjugation. Bioconjug. Chem. 22, 1723–1728 (2011).
Koseoglu, M., Hur, A., Atay, A. & Cuhadar, S. Effects of hemolysis interferences on routine biochemistry parameters. Biochem. Med. (Zagreb) 21, 79–85 (2011).
Acknowledgements
We thank S. Mathieu, D. Boulay, S. Divakaramenon, K. Bowman, V. Vathipadiekal, M. Melkonian, J.C. Dodart, H. Yang, Y. (Benny) Yin, F. Desai and Z. Zhong of Wave Life Sciences for helpful discussions and support for experiments. We thank T. Wada of Tokyo University of Science for general discussions regarding the original oxazaphospholidine method. We thank U. Shigdel of Harvard University (present affiliation, Warp Drive Bio) for purifying the human RNase HC protein. We thank W. Yang of National Institute of Diabetes and Digestive and Kidney Diseases for providing the human RNase HC clone. While at RA Capital Management, A. Donner (present affiliation, The Chemical Probes Portal) provided expert assistance on production of the manuscript.
Author information
Authors and Affiliations
Contributions
All authors contributed to the designing, planning and/or data collection of this project. N.I. designed and developed the SOSICS platform. N.I., D.C.D.B., I.Z., S.M.S. and G.L. carried out the synthesis and characterization of ASOs and reagents. N.I. and Meena conducted rat liver homogenate stability studies and rat serum stability studies. N.I., S.M., N.S. and Meena conducted RNase HC cleavage studies. N.S., L.H.A., M.F.-K. and J.J.Z. performed in vitro and in vivo biological analyses. N.I. and G.L.V. wrote the manuscript, and all authors refined the manuscript.
Corresponding author
Ethics declarations
Competing interests
Wave Life Sciences filed patent applications on this work. G.L.V. is one of the co-founders of Wave Life Sciences and serves as the chairman of the board of directors. D.W.Y.S. was a consultant under contract with Wave Life Sciences. N.I., D.C.D.B., N.S., S.M., I.Z., Meena, S.M.S., G.L., L.H.A., M.F.K., J.J.Z. and C.V. are or were employed by Wave Life Science.
Integrated supplementary information
Supplementary Figure 1 Synthesis of 3’-O-oxazaphospholidine monomers. All oxazaphospholidine monomers were synthesized according to published protocols with minor modifications.
DMTr, 4,4’-dimethoxytrityl; Et3N, triethylamine; Ph, phenyl; THF, tetrahydrofuran
Supplementary Figure 2 Reversed-phase HPLC data for dimers (Sp)-8a-i and (Rp)-8a-i and purified ASOs mipomersen and WV-1-7.
Sp dimers (left column, top to bottom: (Sp)-8a [(Sp)-d(AsT)], (Sp)-8b [(Sp)-d(GsT)], (Sp)-8c [(Sp)-d(5mCsT)], (Sp)-8d [(Sp)-d(CsT)], (Sp)-8e [(Sp)-d(TsT)], (Sp)-8f [(Sp)-A(MOE)sdT], (Sp)-8g [(Sp)-G(MOE)sdT], (Sp)-8h [(Sp)-5mC(MOE)sdT], (Sp)-8i [(Sp)-T(MOE)sdT]) and Rp dimers (center column, top to bottom: (Rp)-8a [(Rp)-d(AsT)], (Rp)-8b [(Rp)-d(GsT)], (Rp)-8c [(Rp)-d(5mCsT)], (Rp)-8d [(Rp)-d(CsT)], (Rp)-8e [(Rp)-d(TsT)], (Rp)-8f [(Rp)-A(MOE)sdT], (Rp)-8g [(Rp)-G(MOE)sdT], (Rp)-8h [(Rp)-5mC(MOE)sdT], (Rp)-8i [(Rp)-T(MOE)sdT]) were eluted using different gradients (see Methods). Dimers were synthesized to demonstrate stereochemical control of synthesis. Absorbance at 254 nm is shown with respect to elution time (min) for each dimer. Purified ASOs (right column, top to bottom: Mipomersen, WV-1, WV-2, WV-3, WB-4, WV-5, WV-6, WV-7), showing purity on C18 column with elution time (x axis, min) and Absorbance at 254 nm (y axis).
Supplementary Figure 3 Diastereomixture and stereochemically pure ASOs show different behaviors on reversed-phase and ion-exchange HPLC.
(a) Ion-exchange HPLC absorbance profiles of mipomersen and WV-1-6. (b) Reverse-phase HPLC data of mousomersen (the mouse sequence of mipomersen, see Supplementary Table 3) and WV-8-11. (c) Ion-exchange HPLC data of mousomersen and WV-8-11. Elution time (x axis) and Absorbance (Abs.) at 254 nm (y axis) are shown. Light green curves show the gradients of percentage of buffer B.
Supplementary Figure 4 Determination of initial velocities (V0) for WV-5 and mipomersen in RNase HC cleavage experiment.
Slope of the best fit line (V0) for WV-5 was 6.90 ± 0.54 μM/min and mipomersen was 2.37 ± 0.20 μM/min under the conditions described in Methods.
Supplementary Figure 5 Dose-response data for mipomersen and ASOs, WV-1-6, in cultured HepB3 cells.
APOB100 mRNA levels were quanitified by RT-PCR and standardized to GAPDH. There is no correlation between potency (IC50) in these assays and efficacy in mice (Fig. 5). Error bars indicate s.d. (n=3), and statistical analysis was performed in Graphpad Prism 6.01.
Supplementary Figure 6 Mipomersen dose-finding study.
Mipomersen was dosed by intraperitoneal injection on days 1, 4, 8, 11, 15, 18, 22, 25, 29, 32, 36, and 39. Human APOB serum protein (shown as a percentage compared with PBS control) dose-dependently decreases in response to mipomersen at days 17 and 24 (n=5 mice per group). We opted for the 10 mg/kg dose in subsequent experiments.
Supplementary Figure 7 Comparative efficacy and duration of action study data.
(a) Human APOB100 serum protein levels (shown as percentage compared with PBS control) decreases in response to 10 mg/kg mipomersen or its components, and recovers in the wash out period (Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32; blood collection days 17, 24, 31, 38, 45, 52, 60, 66; n=5 mice per group, error bars represent s.d.). (b) The concentration of WV-5, WV-6 and mipomersen persisting in mouse liver (μg/g) on days 3, 24 and 45 (n=4, error bars represent s.d.) is shown. The concentrations of the ASOs detected at each time point were not statistically significantly different. (c) LC-MS quantification of ASOs in the liver. Calibration curves for mipomersen, WV-5 and WV-6 were generated using the protocol described with a concentration range of 5-500 μg/g. The oligonucleotides were detected using selected reaction monitoring for the following transitions involving loss of phosphate from intact oligonucleotide: m/z 896.5 ◊ 94.9 for mipomersen, WV-5 and WV-6, and m/z 855.9 ◊ 94.9 for the internal standard.
Supplementary Figure 8 Chemical structure of WV-12 (top) and WV-13 (bottom).
(a) ASOs are GalNAc-conjugated, 20mer PS oligonucleotides composed of unmodified 10-nucleotide DNA cores and 2′-MOE-modified ends. C is 5MeC in the 2′-MOE modified ends. Complementary RNA strand (human APOC3 mRNA): rArUrArArArGrCrUrGrGrArCrArArGrArArGrCrU. (b) Ion-exchange HPLC data for WV-12 (left) and WV-13 (right). Absorbance at 254 nm is shown with respect to elution time (min) for each oligo.
Supplementary Figure 9 WV-12 (black) and WV-13 (pink) persists in mouse liver on day 78 (n=5, error bars represent s.d.).
The concentrations of the ASOs (μg/g) detected were not statistically significantly different.
Supplementary information
Rights and permissions
About this article
Cite this article
Iwamoto, N., Butler, D., Svrzikapa, N. et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat Biotechnol 35, 845–851 (2017). https://doi.org/10.1038/nbt.3948
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3948
This article is cited by
-
Asymmetric synthesis of P-stereogenic phosphindane oxides via kinetic resolution and their biological activity
Nature Communications (2024)
-
Therapeutic approaches for Duchenne muscular dystrophy
Nature Reviews Drug Discovery (2023)
-
Universal and divergent P-stereogenic building with camphor-derived 2,3-diols
Communications Chemistry (2023)
-
Discovering covalent inhibitors of protein–protein interactions from trillions of sulfur(VI) fluoride exchange-modified oligonucleotides
Nature Chemistry (2023)
-
Precision RNA base editing with engineered and endogenous effectors
Nature Biotechnology (2023)